And while it may not feel like it with the sp languishing at multi year lows- POH is just a couple of milestones away from a deal on its lead Pipeline product which according to POHs CEO could dwarf that achieved by ACR. Have a look at the history of Acrux's sp leading up to its landmark Eli Lilly deal on Axiron.
According to Tim Boreham "The deal, claimed to be the biggest licensing arrangement entered into by a local biotech, has a headline value of ``up to'' $US335 million ($367m) -- plus royalties believed to be worth about two-thirds of this ($US220m)."
Just 12 months prior to this deal ACR had traded at sub 50cts.
wind change, page-5
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.32K | 440K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 40522233 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 40065430 | 31 |
View Market Depth
| Last trade - 14.05pm 15/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |